<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>药春秋 | wechat-feeds</title><link>http://MzI0MDM2NTA4NQ.favicon.privacyhide.com/favicon.ico</link><description>医药行业一致性评价工作在如火如荼的进行中，作为行业的一份子，愿本愚公之念，出蝼蚁 之力，献寸光之策。</description><managingEditor> (hellodword)</managingEditor><pubDate>Thu, 22 Apr 2021 23:26:26 +0800</pubDate><image><url>http://MzI0MDM2NTA4NQ.favicon.privacyhide.com/favicon.ico</url><title>药春秋 | wechat-feeds</title><link>http://MzI0MDM2NTA4NQ.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>微球技术哪家强？且看四大领头玩家强势领跑</title><link>https://mp.weixin.qq.com/s/BRaQZmAmbNEn61SSACNAVw</link><description></description><content:encoded><![CDATA[微球技术哪家强？且看四大领头玩家强势领跑]]></content:encoded><pubDate>Thu, 22 Apr 2021 21:41:57 +0800</pubDate></item><item><title>抗凝新力军 - 艾多沙班，踏上“医保”的巨轮乘风破浪吧！</title><link>https://mp.weixin.qq.com/s/9xy7nhcFg0Cjbx40lLukPw</link><description></description><content:encoded><![CDATA[抗凝新力军 - 艾多沙班，踏上“医保”的巨轮乘风破浪吧！]]></content:encoded><pubDate>Thu, 22 Apr 2021 21:41:57 +0800</pubDate></item><item><title>定了！医保、采购金额前80%等品种，通通纳入集采！</title><link>https://mp.weixin.qq.com/s/1_GTy_NOSJI7JgG0nxdn1g</link><description></description><content:encoded><![CDATA[定了！医保、采购金额前80%等品种，通通纳入集采！]]></content:encoded><pubDate>Thu, 22 Apr 2021 21:41:57 +0800</pubDate></item><item><title>NMPA成绩单：一致性评价申请881件，仿制批件722个...</title><link>https://mp.weixin.qq.com/s/QGOzYdGthMzfCaoELLqYBw</link><description></description><content:encoded><![CDATA[NMPA成绩单：一致性评价申请881件，仿制批件722个...]]></content:encoded><pubDate>Thu, 22 Apr 2021 21:41:57 +0800</pubDate></item><item><title>（2021.4.21）最新过评名单；7亿抗菌注射剂，齐鲁先行拿下！</title><link>https://mp.weixin.qq.com/s/H2q9dFwnBmeiUky80dFeGw</link><description></description><content:encoded><![CDATA[（2021.4.21）最新过评名单；7亿抗菌注射剂，齐鲁先行拿下！]]></content:encoded><pubDate>Wed, 21 Apr 2021 21:40:22 +0800</pubDate></item><item><title>三层次梯度降价，国采非中选药机会来了！</title><link>https://mp.weixin.qq.com/s/8V42k1kHs764EvIIM09OLQ</link><description></description><content:encoded><![CDATA[三层次梯度降价，国采非中选药机会来了！]]></content:encoded><pubDate>Wed, 21 Apr 2021 21:40:22 +0800</pubDate></item><item><title>17个短缺药新增挂网</title><link>https://mp.weixin.qq.com/s/BHdM5iKh-1FfWqKgiZH_8A</link><description></description><content:encoded><![CDATA[17个短缺药新增挂网]]></content:encoded><pubDate>Wed, 21 Apr 2021 21:40:22 +0800</pubDate></item><item><title>小科普丨快速了解药品从研发到上市的全过程</title><link>https://mp.weixin.qq.com/s/OHBTpORFdIyLFrxFxnzGZw</link><description></description><content:encoded><![CDATA[小科普丨快速了解药品从研发到上市的全过程]]></content:encoded><pubDate>Wed, 21 Apr 2021 21:40:22 +0800</pubDate></item><item><title>集采后时代 - 他汀类药物还剩多少余量？</title><link>https://mp.weixin.qq.com/s/3Fhg-rE72Ztm1MJcgUCv5w</link><description></description><content:encoded><![CDATA[集采后时代 - 他汀类药物还剩多少余量？]]></content:encoded><pubDate>Tue, 20 Apr 2021 21:38:18 +0800</pubDate></item><item><title>知名重磅注射液，再现降价潮！</title><link>https://mp.weixin.qq.com/s/hj5uSDl0vmGJvEf06BlA5g</link><description></description><content:encoded><![CDATA[知名重磅注射液，再现降价潮！]]></content:encoded><pubDate>Tue, 20 Apr 2021 21:38:18 +0800</pubDate></item><item><title>国采非中选药价格调整，大批原研产品在列...</title><link>https://mp.weixin.qq.com/s/iMTh08VbJwT0Jk9NHEFghQ</link><description></description><content:encoded><![CDATA[国采非中选药价格调整，大批原研产品在列...]]></content:encoded><pubDate>Tue, 20 Apr 2021 21:38:18 +0800</pubDate></item><item><title>「4+7」品种出现供应短缺？</title><link>https://mp.weixin.qq.com/s/m1bmJ1gq6D4X5o_RJnT9Rw</link><description></description><content:encoded><![CDATA[「4+7」品种出现供应短缺？]]></content:encoded><pubDate>Tue, 20 Apr 2021 21:38:18 +0800</pubDate></item><item><title>（2021.4.19）4品种首家过评，涉及齐鲁、华东、华海…</title><link>https://mp.weixin.qq.com/s/kG0NGRTJQN__ISS7XiPa2g</link><description></description><content:encoded><![CDATA[（2021.4.19）4品种首家过评，涉及齐鲁、华东、华海…]]></content:encoded><pubDate>Mon, 19 Apr 2021 21:41:06 +0800</pubDate></item><item><title>279品规集采来袭，分A、B两组展开角逐...</title><link>https://mp.weixin.qq.com/s/A2Z50zJR5jyTdbLAY7HFYQ</link><description></description><content:encoded><![CDATA[279品规集采来袭，分A、B两组展开角逐...]]></content:encoded><pubDate>Mon, 19 Apr 2021 21:41:06 +0800</pubDate></item><item><title>一大批过评药新增挂网（附：最新采购价）</title><link>https://mp.weixin.qq.com/s/zTUfqV8BuaqqSf2ZM7EeiQ</link><description></description><content:encoded><![CDATA[一大批过评药新增挂网（附：最新采购价）]]></content:encoded><pubDate>Mon, 19 Apr 2021 21:41:06 +0800</pubDate></item><item><title>基药目录调整，传出最新消息！</title><link>https://mp.weixin.qq.com/s/fbSewjMc9BHbK5Q4mXzzCQ</link><description></description><content:encoded><![CDATA[基药目录调整，传出最新消息！]]></content:encoded><pubDate>Mon, 19 Apr 2021 21:41:06 +0800</pubDate></item><item><title>【项目合作】热门糖尿病药，与二甲双胍组个CP，杀过去！</title><link>https://mp.weixin.qq.com/s/lAtmD9E7S_lsOTMNO1yy-Q</link><description></description><content:encoded><![CDATA[【项目合作】热门糖尿病药，与二甲双胍组个CP，杀过去！]]></content:encoded><pubDate>Sun, 18 Apr 2021 22:16:20 +0800</pubDate></item><item><title>索马鲁肽VS同类药物，一场豪赌！</title><link>https://mp.weixin.qq.com/s/2H7lBtSdhiqhzPmMECFViw</link><description></description><content:encoded><![CDATA[索马鲁肽VS同类药物，一场豪赌！]]></content:encoded><pubDate>Sun, 18 Apr 2021 22:16:20 +0800</pubDate></item><item><title>李永康精讲：“药品研发分析和QC实验室合规管理的优化与创新” 专题研修班</title><link>https://mp.weixin.qq.com/s/ADRZ1Al0QdeeR5nCIIsfAQ</link><description></description><content:encoded><![CDATA[李永康精讲：“药品研发分析和QC实验室合规管理的优化与创新” 专题研修班]]></content:encoded><pubDate>Sun, 18 Apr 2021 22:16:20 +0800</pubDate></item><item><title>医药销售被裁！药都能卖出去，还怕自己卖不出去？</title><link>https://mp.weixin.qq.com/s/jPfAU4o7SKChDOFSSLsq3g</link><description></description><content:encoded><![CDATA[医药销售被裁！药都能卖出去，还怕自己卖不出去？]]></content:encoded><pubDate>Sat, 17 Apr 2021 21:43:42 +0800</pubDate></item></channel></rss>